Frequency of Refractory Hypertension in Turkish Patients and Evaluation of the Factors Affecting Refractory Hypertension

Mustafa Temizel1,*, Ugur Dilek Calap1, Murtaza Cit1, Mansur Azermir1, Yucel Arman2

1Medicana International Hospital, Department of Internal Medicine, School of Medicine, Biruni University, Istanbul, Turkey
2Department of Internal Medicine, Okmeydani Training and Research Hospital, Istanbul, Turkey

Email address:
mustafatemizel@yahoo.com.tr (M. Temizel), dilekrahmanoglu@gmail.com (U. D. Calap), murtaza.cit@gmail.com (M. Cit), drazermir@hotmail.com (M. Azermir), dryarman@yahoo.com (Y. Arman)

*Corresponding author

To cite this article:
doi: 10.11648/j.ajim.20210901.14

Received: December 15, 2020; Accepted: January 15, 2021; Published: January 22, 2021

Abstract: Background: This study aimed to determine the frequency of refractory hypertension (RH) and investigate the factors affecting RH in Turkish hypertensive patients. Materials and methods: Totally 400 hypertensive patients (114 males and 286 females) were enrolled. Blood pressure (BP) was measured by patients at home two times a day. The patients were called for controlling in every four weeks, and those who had BP <140/90 mmHg were not followed-up. In patients with BP >140/90 mmHg drug doses were increased or another antihypertensive drug was added and the patients were continued to be followed-up. The total follow-up period was 36 weeks. Patients with persisting BP >140/90 mmHg despite triple medication administration including a diuretic form at least for 3 months at adequate doses were considered to have RH. Results: A total of 63 patients (15.8%), including 14 males and 49 females, were considered to have RH. Body Mass Index (BMI) values of patients with and without RH were 32.16±3.56 and 29.71±3.42, respectively (t=2.92; p=0.005). The rate of obese and morbidly obese patients was higher in the RH group (p<0.005). Duration of hypertension was longer in the RH group (9.7±5.6 vs 7.0±5.7 years, p<0.001). Conclusion: We found the frequency of RH as 15.8%. There’s a significant correlation between BMI and RH. Duration of hypertension increases the prevalence of RH, and should be considered one of the risks for RH.

Keywords: Hypertension, Antihypertensive Agents, Blood Pressure

1. Introduction

Hypertension is one of the foremost causes of morbidity and mortality, affecting almost every organ systems in the body. It is suggested that approximately one billion people are affected by hypertension worldwide [1]. The estimated prevalence of hypertension is 29.3% in the general population [2] and 66.3% in the elderly [3]. In patients with hypertension, an increased risk for cardiovascular, cerebrovascular, and renal events have been reported [4, 5]. The Framingham Heart Study defined that with an increase in severity of hypertension, the risk of major cardiovascular events increases in all age groups [6]. Moreover, Lewington et al determined that mortality due to ischemic heart disease and stroke increases gradually with a systolic BP (SBP) of higher than 115 mmHg and a diastolic BP (DBP) of higher than 75 mmHg [7].

Practice guidelines for the management of hypertension recommend a BP goal of <140/90 mmHg [8, 9]. More stringent measures are recommended for patients with diabetes [8, 10] and proteinuric chronic renal failure [8, 11]. Hypertension is difficult to control despite the use of combinations of antihypertensive drugs in some patients and is considered resistant hypertension.

Hypertension is generally defined as resistant or refractory to treatment if systolic and diastolic BP goal levels could not be reached, despite a therapeutic plan including lifestyle measures and the prescription of at least three medications
(including a diuretic) at appropriate, excluding isolated office hypertension [8].

In this study, we aimed to examine the frequency of RH and to investigate the factors affecting RH in Turkish hypertensive patients.

2. Materials and Methods

In this study, 400 patients previously diagnosed with essential hypertension were enrolled.

The exclusion criteria included a history of any chronic cerebrovascular, cardiovascular, renal, hepatic, pancreatic or metabolic diseases, uncontrolled type 2 diabetes (glycosylated hemoglobin >8.5%) and patients over 80 years of age.

Medication usage was assessed during the screening visit. Drug classes included angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARB), beta-blockers, calcium channel blockers (dihydropyridine and nondihydropyridine), diuretics (thiazide and potassium-sparing), alpha-adrenergic receptor antagonists (Doxazosin), and central-acting drugs (Rilmenidin).

The patients were questioned for age, duration of hypertension, educational status, smoking habit, and diabetes status. Standardized anthropometric measurements (weight, height) were obtained on individuals in light clothing. BMI was calculated as body weight divided by height squared (kg/m$^2$). Serum lipid levels (low density lipoprotein, high density lipoprotein, very low density lipoprotein and Triglyceride levels) were measured in all patients (Table 1).

All patients measured SBP and DBP using a digital sphygmomanometer at home. Patients were trained in the BP measurement method and tested. All BP measuring devices were checked for accuracy.

BP was measured by patients two times a day (in the morning, and the afternoon or evening). The patients were followed for 36 weeks.

The patients were called for controlling in every four weeks, and those who had BP <140/90 mmHg were not followed-up.

In patients with BP >140/90 mmHg drug doses were increased or another antihypertensive drug was added and the patients were continued to be followed-up.

Patients with persisting BP >140/90 mmHg despite an administration of a triple medication including a diuretic form at least for 3 months at adequate doses were considered to have RH.

Patients were grouped according to the hypertension status and the results were compared between the patients with and without RH.

Statistical analyses were performed with SPSS version 16 software for Windows. The comparison between the patients with and without RH was made via the chi-square test and differences in the values of the variables between the groups were evaluated by the Mann Whitney-U test. The degree of the correlation between parameters was evaluated by regression analysis. A value of $p<0.05$ was considered to be statistically significant.

3. Results

A total of 400 patients, 114 males (28.5%) and 286 females (71.5%), were evaluated in the study.

In the first follow-up (week four) 152 (38%) participants, including 35 (31%) men and 117 (41%) women, had controlled hypertension and their follow-up did not continue.

During the study, 63 patients (15.8%) were considered to have RH, including 14 males and 49 females.

There were no significant differences between the groups regarding gender ($p=0.128$), age ($p=0.809$), educational status ($p=0.465$), diabetes ($p=0.107$), serum lipid levels ($p=0.614$) or smoking ($p=0.959$).

BMI values of patients with and without RH were detected as 32.16±3.56 and 29.71±3.42, respectively. The difference between groups was statistically significant ($t=2.92; p=0.005$). The rate of obese and morbidly obese patients was higher in the RH group ($p<0.005$) (Table 1).

Duration of hypertension was longer in the RH group: 9.7±5.6 vs 7.0±5.7 years ($p<0.001$) (Table 1).

In the regression analysis, coefficients of effective factors were analyzed; the effect capacity was 1.085 for BMI and 1.077 for the duration of hypertension (Table 2).

We could not find any cut-off value in ROC analysis of BMI and duration of hypertension to determine the RH.

Table 1. Baseline clinical characteristics of the study groups.

<table>
<thead>
<tr>
<th>Variables</th>
<th>RH group (n=64)</th>
<th>Non-RH group (n=337)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender (n, %)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>14 (22.2)</td>
<td>103 (29.3)</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>49 (77.8)</td>
<td>234 (70.7)</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>63 (15.8)</td>
<td>337 (84.2)</td>
<td></td>
</tr>
<tr>
<td>Age (years, mean±SD)</td>
<td>57.8±9.6</td>
<td>58±10.8</td>
<td></td>
</tr>
<tr>
<td>Education level (n, %)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Illiterate</td>
<td>26 (41.3)</td>
<td>131 (38.9)</td>
<td></td>
</tr>
<tr>
<td>Literate</td>
<td>6 (9.5)</td>
<td>36 (10.7)</td>
<td></td>
</tr>
<tr>
<td>Primary school</td>
<td>30 (47.6)</td>
<td>151 (44.8)</td>
<td></td>
</tr>
<tr>
<td>High school-Univers.</td>
<td>1 (1.6)</td>
<td>19 (5.6)</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>63</td>
<td>337</td>
<td></td>
</tr>
<tr>
<td>Duration of HT (years, mean±SD)</td>
<td>9.7±5.6</td>
<td>7.0±5.7</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Diabetes presence (n %)</td>
<td>20 (31.7)</td>
<td>75 (22.3)</td>
<td>0.107</td>
</tr>
<tr>
<td>Smoker status (n %)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
The purpose of treatment in hypertensive patients is to reduce the long-term cardiovascular morbidity and mortality rates by controlling BP and other risk factors [8]. However, despite the known risks associated with hypertension and the variety of effective antihypertensive medications available, BP control remains suboptimal. In an analysis of NHANES participants under antihypertensive treatment, only 53% were having a BP <140/90 mmHg [12]. In Framingham Heart Study, only 48% of treated participants were reported to have a BP<140/90 mmHg and among elderly participants (>75 years of age) less than 40% were having a goal BP [13]. In patients with diabetes mellitus or chronic kidney disease (CKD), the ratio of uncontrolled hypertension was higher. Of NHANES participants with CKD barely 37%, and of participants with diabetes just 25% were reported to have a BP <130/85 mmHg [12, 14]. In our study, only 152 (38%) participants were at a goal BP in the first follow-up (week four), which shows an insufficient BP control close to high-risk groups.

The exact prevalence of RH is unknown. The estimated prevalence of RH in large trials for instances the ALLHAT, VALUE, ASCOTT, and CONVINCE trials, was 7-15% [15-18]. Previous studies suggested the prevalence of RH in tertiary care centers as 5-18% [19-21], while a large cohort study by Alderman et al. reported the prevalence of RH as low as 2.9% [22]. Some clinical trials pointed out that the RH was gradually more widespread. In the Systolic Hypertension in Europe (Syst-Eur) study, 43% of patients were determined to have RH [23], but isolated systolic hypertension in the elderly was frequently not incorporated in the assessments of prevalence of RH. In the LIFE (Losartan Intervention for Endpoint Reduction in Hypertension) study, which included hypertensive patients with left ventricular hypertrophy, 26% of the patients were defined as having RH [24]. However, these numbers overrate the prevalence of RH as they are performed with older or high-risk patients. In our study we have obtained the frequency of RH similar to other studies (15.8%).

Unfortunately, the exact prevalence of RH will most likely remain to be unknown, since it is not quite possible to perform a prospective study with appropriate drug titrations in the general hypertensive population.

The reasons for a poor response are numerous: poor adherence to the therapeutic regimens, potential drug interactions, high salt or alcohol intake, the use of banned drugs, volume overload, sleep apnoea, and obesity. Except for these known factors, we thought that there may be other factors that affect resistance to treatment of hypertension and we evaluated the patients for the duration of hypertension, gender, educational status, and smoking habit. We expected better BP control in the patients with a higher level of education or poor BP control in smokers but the results did not support it.

We report a significant correlation between BMI and resistance to hypertension treatment (p=0.005). Furthermore, the rate of obese and morbidly obese patients was higher in the RH group (p<0.005). Weight gain increases the incidence of hypertension. The effect of weight gain was shown in a study of more than 80,000 women participating in the Nurse’ Health Study [25]. Those women who had gained as little as 5 kg over their weight at age 18 had a 60% higher relative risk of developing hypertension than did those whose weight had not changed more than 2 kg; moreover gaining 10 kg or more, caused a 2.2-fold greater risk. In a cross-sectional study, adults with a BMI>40 had 6.38 times greater odds ratio for hypertension [26]. Data from NHANES III shows that the prevalence of high BP augments gradually with increased levels of BMI in men and women; additionally, a progressive increase in the prevalence of hypertension was
determined with elevated BMI values at all ages [27].

We also report a significant correlation between the duration of hypertension and resistance to hypertension treatment. Duration of hypertension was longer in the RH group - 9.7±5.6 vs 7.0±5.7 years (p<0.001). The patients with a longer duration of hypertension had more difficulty to respond to medical treatment.

The need for higher dosage and more medications with the elongation of the duration of hypertension is a common observation. Many questions arise about this. In fact, antihypertensive drugs are limited in terms of variation. Could the continuous effect of the same medication molecules on the same receptors cause a change (‘abrasion’) in the receptor after a while? Could the non-response to the treatment be owing to the ineffectiveness caused by duration? Is a good BP control sufficient reason not to change the treatment? Would a change in medication from time to time be thought just to overcome ‘abrasion’? Even though it is not a strong antihypertensive drug (but a different molecule), the benefit of adding spironolactone in reducing BP supports this thought. The close association of the aldosterone status with RH resulted in a basis for the addition of spironolactone. We have preferred daily BP measuring at home, all the patients had experience in measuring BP. We checked the devices that were brought to us, but we cannot claim that all the devices were checked. Even though some setbacks occurred in daily measurements and making notes of BP measurements; the patients made a satisfactory effort in this regard. The fact that the study was done in a metropolis like Istanbul, with understandable reasons, made it difficult for the patients to come for regular follow-ups. Therefore, the planned 24-week patient follow-up process was extended to 36 weeks.

5. Conclusions

The mainstay of the treatment of RH is the removal of exogenous factors and the use of the maximum tolerated doses of combined antihypertensive agents. To attain and maintain goal BP, using multiple drugs, changes in medications and more aggressive strategies should not be avoided. With increasing BMI, BP control gets difficult and increases resistance to treatment. If the duration of hypertension gets longer, it increases the risk of resistance to treatment. In this respect, the duration of hypertension should be considered one of the risks for RH.

References


